Food and Drug Administration
Bureau of Drugs
5600 Fishers Lane
Rockville, Maryland 20852

November 1, 1970

This list represents those drug products which the Food and Drug Administration has decided, after evaluations by the National Academy of Sciences-National Research Council Drug Efficacy Study Group, lack substantial evidence of effectiveness*, or that an unfavorable benefit to risk ratio exists. Accordingly, on the dates shown, FDA published in the Federal Register announcements of intention to initiate proceedings to withdraw approval of the new drug applications or to repeal the antibiotic regulations. These announcements are intended to apply also to similar drug products marketed by the same or other firms.

Some of the products have been removed from the market; others are the subjects of actions contesting our findings. In other cases the applicants are submitting data in an attempt to establish efficacy, or making changes to render the product acceptable.

NAME OF DRUG	COMPANY	DATE
Achrocidin Compound Syrup	Lederle Laboratories	9/12/69
Achrocidin Compound Tablets	Lederle Laboratories	9/12/69
Achromycin Pharyngets	Lederle Laboratories	9/19/70
Achromycin SV Capsules	Lederle Laboratories	4/2/69
Achromycin Troches	Lederle Laboratories	9/19/70
Achromycin with Phenylephrine HCl and HC	Lederle Laboratories	12/24/68
Achrostatin V Capsules	Lederle Laboratories	4/2/69
Achrostatin V for Oral Suspension	Lederle Laboratories	4/2/69
Aclor Capsules	Cole Pharmacal Co., Inc.	9/12/69
Acticort	Wilson Laboratories	9/25/70
Actilamide Nose Drops	Broemmel Pharmaceuticals	11/6/68
Actilamide Oral Gargle	Broemmel Pharmaceuticals	11/6/68
Actilamide Throat Spray	Broemmel Pharmaceuticals	11/6/68
Actol Solution	The S.E. Massengill Co.	5/16/70

*As defined in the Federal Food, Drug and Cosmetic Act